What is isatuximab? And how does it compare with daratumumab?

Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myelomaПодробнее

Choosing between isatuximab & daratumumab in multiple myelomaПодробнее

Dr. Harrison on Subcutaneous Daratumumab and Isatuximab in MyelomaПодробнее

Daratumumab and isatuximab in the treatment of multiple myelomaПодробнее

All About Sarclisa (Isatuximab) #myelomaПодробнее

Daratumumab vs isatuximab in the treatment of multiple myelomaПодробнее

Robert M. Rifkin, MD, FACP, explains how isatuximab differs from daratumumabПодробнее

ITHACA trial results: combination of isatuximab, lenalidomide & dexamethasone for high-risk SMMПодробнее

ICARIA study: Isatuximab and pom/dex for multiple myelomaПодробнее

Isatuximab Plus Pomalidomide/Low-Dose Dex Vs Pomalidomide/Low-Dose Dex in Pts with RRMM (ICARIA-MM)Подробнее

Final results of isatuximab in combinations to treat r/r MMПодробнее

The safety and efficacy of isatuximab for R/R myeloma: insights from ICARIA-MM, IKEMA & CANDORПодробнее

Isatuximab for multiple myeloma - promising results and next stepsПодробнее

Isatuximab, Pomalidomide, and Dexamethasone for Relapsed/Refractory MyelomaПодробнее

Isatuximab: a ‘next-generation monoclonal antibody’Подробнее

MOA and Safety Profile of Isatuximab from the ICARIA StudyПодробнее

Isatuximab plus Pomalidomide and Low-Dose Dex (Pd) Versus Pd In Relapsed and Refractory MMПодробнее

The role of isatuximab in the management of MMПодробнее

What does the FDA approval of Sarclisa® (isatuximab) mean for myeloma patients?Подробнее